BR112023022114A2 - Composto farmacêutico compreendendo agonista de gpr40 e inibidor de sglt-2 - Google Patents

Composto farmacêutico compreendendo agonista de gpr40 e inibidor de sglt-2

Info

Publication number
BR112023022114A2
BR112023022114A2 BR112023022114A BR112023022114A BR112023022114A2 BR 112023022114 A2 BR112023022114 A2 BR 112023022114A2 BR 112023022114 A BR112023022114 A BR 112023022114A BR 112023022114 A BR112023022114 A BR 112023022114A BR 112023022114 A2 BR112023022114 A2 BR 112023022114A2
Authority
BR
Brazil
Prior art keywords
sglt
inhibitor
gpr40 agonist
pharmaceutical compound
same
Prior art date
Application number
BR112023022114A
Other languages
English (en)
Inventor
Hae Hong Da
Gil Lee Don
Jin Song Haeng
Chul Yoon Hong
Gyu Je In
Min Yoon Jong
Tae Park Joon
Woo Lee Jung
Mi An Kyung
Original Assignee
Ildong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ildong Pharmaceutical Co Ltd filed Critical Ildong Pharmaceutical Co Ltd
Publication of BR112023022114A2 publication Critical patent/BR112023022114A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

composto farmacêutico compreendendo agonista de gpr40 e inibidor de sglt-2. a presente invenção compreende uma composição farmacêutica incluindo um agonista de gpr40 e um inibidor de sglt-2, um método de preparação dos mesmos e um método de tratamento de diabetes mellitus tipo 2 e doenças semelhantes usando os mesmos.
BR112023022114A 2021-04-29 2022-04-28 Composto farmacêutico compreendendo agonista de gpr40 e inibidor de sglt-2 BR112023022114A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20210055992 2021-04-29
PCT/KR2022/006120 WO2022231357A1 (en) 2021-04-29 2022-04-28 Pharmaceutical composition comprising gpr40 agonist and sglt-2 inhibitor

Publications (1)

Publication Number Publication Date
BR112023022114A2 true BR112023022114A2 (pt) 2024-01-30

Family

ID=83848392

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023022114A BR112023022114A2 (pt) 2021-04-29 2022-04-28 Composto farmacêutico compreendendo agonista de gpr40 e inibidor de sglt-2

Country Status (13)

Country Link
EP (1) EP4329756A1 (pt)
JP (1) JP2024515137A (pt)
KR (1) KR20240004285A (pt)
CN (1) CN117241798A (pt)
AR (1) AR125494A1 (pt)
AU (1) AU2022266499A1 (pt)
BR (1) BR112023022114A2 (pt)
CA (1) CA3217858A1 (pt)
IL (1) IL307623A (pt)
MX (1) MX2023012835A (pt)
TW (1) TW202308620A (pt)
UY (1) UY39744A (pt)
WO (1) WO2022231357A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102007633B1 (ko) * 2016-12-15 2019-08-06 일동제약(주) 신규 페닐 프로피온 산 유도체 및 이의 용도
KR20240084229A (ko) * 2022-12-06 2024-06-13 유노비아 주식회사 안정성이 향상된 gpr40 효현제를 유효성분으로 포함하는 약제학적 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007033002A1 (en) * 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
US10195178B2 (en) * 2016-04-11 2019-02-05 Janssen Pharmaceutica Nv GPR40 agonists in anti-diabetic drug combinations
CN108430467B (zh) * 2016-05-20 2021-06-22 晟德大药厂股份有限公司 (r)-(+)-维拉帕米用于治疗高血糖的用途及其药学组合物
KR101934328B1 (ko) * 2016-08-12 2019-01-02 주식회사 노브메타파마 아모디아퀸 및 항당뇨 약물을 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 약학적 조성물
KR102007633B1 (ko) * 2016-12-15 2019-08-06 일동제약(주) 신규 페닐 프로피온 산 유도체 및 이의 용도

Also Published As

Publication number Publication date
KR20240004285A (ko) 2024-01-11
MX2023012835A (es) 2023-11-08
WO2022231357A1 (en) 2022-11-03
IL307623A (en) 2023-12-01
JP2024515137A (ja) 2024-04-04
UY39744A (es) 2022-11-30
AU2022266499A1 (en) 2023-11-09
AR125494A1 (es) 2023-07-19
CA3217858A1 (en) 2022-11-03
CN117241798A (zh) 2023-12-15
TW202308620A (zh) 2023-03-01
EP4329756A1 (en) 2024-03-06

Similar Documents

Publication Publication Date Title
BR112023022114A2 (pt) Composto farmacêutico compreendendo agonista de gpr40 e inibidor de sglt-2
BR112021020335A2 (pt) Agonistas glp-1r e usos dos mesmos
CY1123260T1 (el) Ενα αλας νατριου του ν-((1,2,3,5,6,7-eξaϋδpo-s-inδaken-4-υλ)καρβαμοϋλ)-1-ισοπροπυλ-1η-πυραζολο-3-σουλφοναμιδιου
BR112021022624A2 (pt) Compostos para o tratamento da doença de huntington
UY38999A (es) Degradadores de proteína tirosina fosfatasa y métodos de uso de los mismos
BR112021022457A2 (pt) Inibidores de fgfr e métodos de uso dos mesmos
BRPI0511703B8 (pt) composto, composição farmacêutica, e, métodos de tratar diabete melito tipo 2, de retardar o início do diabete melito tipo 2, de tratar hiperglicemia, diabete ou resistência à insulina, obesidade, síndrome x, um distúrbio lipídico, aterosclerose, e uma condição
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
CL2012001722A1 (es) Compuestos derivados de 3-hidroxi-5-arilisotiazol, agonistas del receptor 40 acoplado a la proteina g (gpr40); composición farmacéutica que los comprende; y método para el tratamiento o la prevención de la diabetes.
BRPI0713755A8 (pt) composto ou um sal ou solvato do mesmo, uso do composto ou um sal ou salvato do mesmo, composição farmacêutica,e, processo para a preparação de um composto ou um sal ou solvato do mesmo
BR112021017583A2 (pt) Compostos, composições e métodos para o tratamento de doença
BR0010555A (pt) Inibidores de neuraminidases
ECSP066653A (es) Derivados de bencenosulfonilamino-piridin-2-il y compuestos relacionados como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa tipo 1(ii-beta-hsd-1) para el tratamiento de la diabetes y de la obesidad
EA201300550A1 (ru) Фармацевтическая композиция, способы лечения и их применение
BR112022021381A2 (pt) Compostos para o tratamento de sars
BR112022008786A2 (pt) Composto, composição, uso do composto ou da composição, e, método para tratar ou prevenir uma complicação diabética, doença relacionada à neuroinflamação ou aterosclerose
BR112017021529A2 (pt) composto, composição, método para controlar uma praga e semente tratada
BRPI0514868A (pt) composto, composição farmacêutica, uso de um composto, métodos para produzir um efeito inibidor de hdac em um animal de sangue quente, para tratar ou prevenir cáncer em um animal de sangue quente, e para tratar doenças, e, processo para preparar um composto
CL2021002205A1 (es) Compuesto heterocíclico, composición farmacéutica que lo comprende, método para su preparación, y uso de estos
BR112021018924A2 (pt) Derivado de heterocíclico pirrol, método de preparação do mesmo e aplicação do mesmo em medicamento
BR112021023927A2 (pt) Composto, e, composição farmacêutica
BR112021024325A2 (pt) Análogos de 3-(5-metil-1,3-tiazol-2-il)-n-{(1r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida
BR112022020147A2 (pt) Compostos para tratar a doença de huntington
BR112021024300A2 (pt) Formas de sais cristalinas de um inibidor de quinase
CL2021002397A1 (es) Derivados de insulina sensibles a la glucosa